What Makes Zoetis (ZTS) an Investment Bet?

Core Insights - Diamond Hill Capital's "Mid Strategy" reported a strong performance in Q4 2025, with a return of 3.65% compared to the Russell Midcap Index's 0.16% [1] - The strategy's year-to-date return was 13.47%, outperforming the Russell Midcap Index's 10.60% [1] - AI-related spending was a significant driver in equity markets, although investor caution emerged in December 2025 [1] Company Overview: Zoetis Inc. (NYSE:ZTS) - Zoetis Inc. is a leader in the animal health market, focusing on medications, vaccines, and diagnostic products for both companion animals and livestock [3] - As of March 17, 2026, Zoetis Inc. shares closed at $121.68, with a market capitalization of approximately $53.624 billion [2] - The stock experienced a -5.77% return in the past month and a -25.69% decline over the past twelve months [2] Investment Positioning - Concerns regarding an arthritis drug for dogs have negatively impacted Zoetis Inc.'s share price, creating an opportunity for investment below intrinsic value estimates [3] - Despite its potential, Zoetis Inc. is not among the 40 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, down from 72 in the previous quarter [4] - The company is viewed as having less upside potential compared to certain AI stocks, which are considered to carry less downside risk [4]